We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRL:NYSECharles River Laboratories International, Inc. Analysis

Data as of 2026-08-24 - not real-time

$294.89

Latest Price

8/10Risk

Risk Level: High

Executive Summary

At $294.89, Charles River Laboratories International, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. The last 30 days have gained 28.4%. With RSI at 75.9 the momentum picture is overbought, alongside a bullish MACD signal. Recent trading has carved out support near $227.38 and resistance around $299.32.
Multiples put this in fair territory: 23.2 times earnings against the sector's 31.0. The average analyst target implies 4.7% below today's level. Revenue is contracting at 2.7% on a -6.0% profit margin.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 45.5%, a beta of 1.24 and a maximum drawdown of 33.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.

Top Market Events

Charles River Laboratories International Inc CRL beats Q2 targets with a 1.Charles River CRL delivered earnings and revenue surprises of +11.Lab services company Charles River Laboratories NYSE:CRL reported Q2 CY2026 results beating Wall Street’s revenue...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • RSI at 75.9 signals overbought conditions
  • Trading above the 200-day average of 194.61

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • RSI at 75.9 signals overbought conditions
  • P/E of 23.2 versus sector average of 31.0

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 23.2 versus sector average of 31.0
  • Negative profit margin of -6.0%
  • Negative return on equity of -7.5%

Key Metrics & Analysis

Financial Health

Revenue Growth-2.70%
Profit Margin-5.96%
P/E Ratio23.2
ROE-7.52%
ROA4.11%
Debt/Equity105.05
P/B Ratio5.0
Op. Cash Flow$582.1M
Free Cash Flow$468.9M
Industry P/E31.0

Technical Analysis

TrendBullish
RSI75.9
Support$227.38
Resistance$299.32
MA 20$267.16
MA 50$236.28
MA 200$194.61
MACDBullish
VolumeDecreasing
Fear & Greed Index93.11

Valuation

Fair Value$66.16
Target Price$281.00
Upside/Downside-4.71%
GradeFair
TypeBlend

Risk Assessment

Beta1.24
Volatility45.50%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.